1 / 19

DRAFT

DRAFT. DRAFT. CIRCULATORY SUPPORT DEVICES PANEL Thursday, June 23, 2005. Abiomed, Inc. Abiocor® Implantable Replacement Heart HDE H040006. FDA Review Summary. Abiomed, Inc. Abiocor® Implantable Replacement Heart Eric Chen M.S. FDA/CDRH/ODE/DCD. Overview of Presentation. What is an HDE?

elana
Download Presentation

DRAFT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. DRAFT Abiomed, H040006

  2. DRAFT CIRCULATORY SUPPORTDEVICES PANELThursday, June 23, 2005 Abiomed, Inc. Abiocor® Implantable Replacement Heart HDE H040006

  3. FDA Review Summary Abiomed, Inc. Abiocor® Implantable Replacement Heart Eric Chen M.S. FDA/CDRH/ODE/DCD Abiomed, H040006

  4. Overview of Presentation • What is an HDE? • History of Feasibility Study • Pre-clinical Evaluation • Clinical Evaluation • Panel Questions Abiomed, H040006

  5. M. Berman, Ph.D. E. Chen, M.S. V. Covington D. Fleischer K. Foy, M.S. E. Harvey, Ph.D. D. Headlee M. Mendelson I. Piña, M.D. J. Rinaldi, M.S. W. Scott, Ph.D. J. Swain, M.D. FDA Review Team Abiomed, H040006

  6. What is an Humanitarian Device Exemption? An HDE application is similar in both form and content to a premarket approval (PMA) application, but exempt from the effectiveness requirements of a PMA. An approved HDE authorizes marketing of a Humanitarian Use Device (HUD). (Humanitarian Device Exemption Regulation: Questions and Answers Final Guidance for Industry http://www.fda.gov/cdrh/ode/guidance/1381.pdf) Abiomed, H040006

  7. What is an Humanitarian Use Device? A device that is intended to benefit patients in the treatment and diagnosis of diseases or conditions that affect or is manifested in fewer than 4,000 individuals in the United States per year. (Federal Food, Drug, and Cosmetic Act, http://www.access.gpo.gov/uscode/title21/chapter9_.html) Abiomed, H040006

  8. AbioCor Implantable Components Abiomed, H040006

  9. Abiomed, H040006

  10. Proposed Indication for Use The AbioCor is indicated for use in severe end stage heart disease patients who: • are less than 75 years old, • are not transplant candidates at the time of assessment, • require multiple inotropic support, • are in biventricular failure not treatable by LVAD destination therapy, and • are not weanable from biventricular support if on such support and not awaiting transplantation. Abiomed, H040006

  11. U.S. Feasibility Study • IDE G000329 • Single arm prospective feasibility trial to determine safety of the AbioCor • Sample size of 14 patients • 6 investigational sites • No prospective statistical plan or control group • Incremental gate for study continuation • If none of first 5 patients survived 30 days - stoppage • At least 1 out of 5 patients – survived 60 days • Slow enrollment Abiomed, H040006

  12. Candidate Selection Process • Two stage process • Screening • Determine severity of heart failure (AbioScore) • Potential fit of the AbioCor (AbioFit) • Implant consent Abiomed, H040006

  13. HDE Regulation(21 CFR 814 Subpart H) • REASONABLE assurance of safety and probablebenefit • Factors considered (21 CFR 814.104b) • Patient population • Noothercomparabledeviceavailable (other than another HDE device or device approved under IDE) • Probable benefit vs. probable injury • Clinical experience (21 CFR 814.104b) Abiomed, H040006

  14. Preclinical EvaluationDetermined To Be Satisfactory • Alarms • Battery Performance • Biocompatibility • Electrical Safety and EMC • Manufacturing • Software • Sterilization, packaging, shelf life, shipping Abiomed, H040006

  15. Preclinical EvaluationConcerns Remain • Reliability • Internal components • Membrane wearout • Bearing failure • Device end of life indicator Abiomed, H040006

  16. ReliabilityBench Testing • 25 units on test • Mock circulation loop • Implanted components in 37ºC buffered saline • Failure times between 8.2 to 40.5 months • Average runtime – 18.8 months • Reliability greater than 80% at 80% confidence level for one-year operation • 3 failure modes • Hydraulic membrane wearout • Bearing failure • Fluid ingress Abiomed, H040006

  17. Clinical Failures • Patient #2 • Membrane wearout at 17 months (expected) • Patient refused to have AbioCor replaced • Propose to tighten tolerance on energy converter • Continue to monitor membrane wearout • Patient #13 • Bearing failure at 5 months (unexpected) • Position of AbioCor different than pre-placement CT scans • Corrective actions have been accepted by FDA Abiomed, H040006

  18. Engineering Summary • Replacement requires major surgery • Device end of life behavior seen during bench testing • 2 device malfunctions • 1 membrane wearout • 1 bearing wearout Abiomed, H040006

  19. Summary Results of the pre-clinical testing in conjunction with the outcome of the reliability results from the clinical trial suggest that the device performs according to specifications. Abiomed, H040006

More Related